NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$186.4m

Last Updated

2021/04/11 23:39 UTC

Data Sources

Company Financials +

Executive Summary

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. More Details


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has OptiNose's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OPTN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: OPTN's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

-4.3%

OPTN

-0.8%

US Pharmaceuticals

2.1%

US Market


1 Year Return

-12.9%

OPTN

11.9%

US Pharmaceuticals

56.3%

US Market

Return vs Industry: OPTN underperformed the US Pharmaceuticals industry which returned 11.9% over the past year.

Return vs Market: OPTN underperformed the US Market which returned 56.3% over the past year.


Shareholder returns

OPTNIndustryMarket
7 Day-4.3%-0.8%2.1%
30 Day-8.3%-1.2%2.4%
90 Day-18.9%-2.5%6.8%
1 Year-12.9%-12.9%15.7%11.9%59.1%56.3%
3 Year-82.0%-82.0%29.1%19.0%65.7%55.1%
5 Yearn/a42.2%25.1%122.3%97.7%

Long-Term Price Volatility Vs. Market

How volatile is OptiNose's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OptiNose undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OPTN ($3.52) is trading below our estimate of fair value ($62.77)

Significantly Below Fair Value: OPTN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OPTN is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: OPTN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OPTN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OPTN is overvalued based on its PB Ratio (27.5x) compared to the US Pharmaceuticals industry average (3.9x).


Future Growth

How is OptiNose forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

62.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPTN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: OPTN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OPTN's is expected to become profitable in the next 3 years.

Revenue vs Market: OPTN's revenue (32.1% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: OPTN's revenue (32.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OPTN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has OptiNose performed over the past 5 years?

-27.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OPTN is currently unprofitable.

Growing Profit Margin: OPTN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OPTN is unprofitable, and losses have increased over the past 5 years at a rate of 27.7% per year.

Accelerating Growth: Unable to compare OPTN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OPTN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.8%).


Return on Equity

High ROE: OPTN has a negative Return on Equity (-1470.02%), as it is currently unprofitable.


Financial Health

How is OptiNose's financial position?


Financial Position Analysis

Short Term Liabilities: OPTN's short term assets ($180.7M) exceed its short term liabilities ($52.2M).

Long Term Liabilities: OPTN's short term assets ($180.7M) exceed its long term liabilities ($129.9M).


Debt to Equity History and Analysis

Debt Level: OPTN's debt to equity ratio (1844.5%) is considered high.

Reducing Debt: OPTN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OPTN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OPTN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is OptiNose current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OPTN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OPTN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OPTN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OPTN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OPTN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Peter Miller (59 yo)

11.25yrs

Tenure

US$2,033,498

Compensation

Mr. Peter K. Miller has been the Chief Executive Officer of OptiNose US Inc., since 2010. Mr. Miller has been the Chief Executive Officer at Optinose, Inc. since 2010. He serves as the Chief Executive Offi...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD2.03M) is above average for companies of similar size in the US market ($USD961.12K).

Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: OPTN's management team is considered experienced (4.3 years average tenure).


Board Members

Experienced Board: OPTN's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: OPTN insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.3%.


Top Shareholders

Company Information

OptiNose, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OptiNose, Inc.
  • Ticker: OPTN
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$186.369m
  • Shares outstanding: 52.95m
  • Website: https://www.optinose.com

Number of Employees


Location

  • OptiNose, Inc.
  • 1020 Stony Hill Road
  • Suite 300
  • Yardley
  • Pennsylvania
  • 19067
  • United States

Listings


Biography

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 23:39
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.